Agalsidase alfa - Open Access .click

Results 111 to 120 of about 167,688 (127)

Enzyme replacement therapy with agalsidase alfa in patients with Fabry's disease: an analysis of registry data

Lancet, The, 2009
BACKGROUND: We analysed 5-year treatment with agalsidase alfa enzyme replacement therapy in patients with Fabry's disease who were enrolled in the Fabry Outcome Survey observational database (FOS).
Roberto Giugliani, Aleš Linhart, Frédéric Barbey +2 more
exaly +2 more sources

Some of the next articles are maybe not open access.

Related searches:

fabry disease
enzyme replacement therapy
agalsidase beta

anti-drug antibodies
medicine
therapeutics

migalastat
pharmacology
medicine general

Clinical observation of patients with Fabry disease after switching from agalsidase beta (Fabrazyme) to agalsidase alfa (Replagal)

Genetics in Medicine, 2012
Kazuya Tsuboi
exaly

Changes in plasma and urine globotriaosylceramide levels do not predict Fabry disease progression over 1 year of agalsidase alfa

Genetics in Medicine, 2013
Bruce A Barshop, Kathleen Nicholls
exaly

A randomised, double-blind, placebo-controlled, crossover study to assess the efficacy and safety of three dosing schedules of agalsidase alfa enzyme replacement therapy for Fabry disease

Molecular Genetics and Metabolism, 2013
Derralynn A Hughes, A B Mehta, D A Hughes +2 more
exaly

Agalsidase alfa for the treatment of Fabry disease: new data on clinical efficacy and safety

Expert Opinion on Biological Therapy, 2009
Michael Beck
exaly